SMYD3 and breast cancer: Similarly, combined administration of trametinib and αPD-1 antibody inhibited SMYD3/SHCBP1-dependent breast cancer progression in xenografts by suppressing MEK activation and promoting CD4/8+ cell infiltration [30].